Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Type 2 Diabetes During Ramadan
NCT06635057Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06635057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635057.